Assess whether biosimilarity is analytically justified

Situation

Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — phase-3 protocol with endpoint-sensitivity issues — after an FAERS cluster in a demographic the trials under-enrolled. If phase-3 protocol with endpoint-sensitivity issues cannot support biosimilarity is analytically justified, the honest Pharma & Life Sciences output is hold.

Decision

Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• Phase-3 protocol with endpoint-sensitivity issues reads as Proceed under protocol once an FAERS cluster in a demographic the trials under-enrolled is lined up to the same Pharma & Life Sciences population.
• Phase-3 protocol with endpoint-sensitivity issues is closer to Pause the pathway after an FAERS cluster in a demographic the trials under-enrolled; Proceed under protocol would over-claim this FDA Response and Labeling extract.
• Escalate safety review is still live in phase-3 protocol with endpoint-sensitivity issues for pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT.
• Phase-3 protocol with endpoint-sensitivity issues is missing the fact pediatric-plan strategist needs after an FAERS cluster in a demographic the trials under-enrolled; stop this Pharma & Life Sciences close.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences FDA Response and Labeling file, read phase-3 protocol with endpoint-sensitivity issues against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move biosimilarity is analytically justified for pediatric-plan strategist.

Recommendation